2010-2012

2014-2015

2016-2017

2018-2019

2020-2021

5 years of recognized safety standard OHSAS 18001:2007 Certification
FDA & PMDA approval for MB02.
EMA & FDA inspection at mAbxience Argentina and León respectively.
Expansion of Spanish R&D center at Genhelix.
Launch global CDMO platform strategy to all partners worldwide.
Fresenius Kabi acquires a majority stake in mAbxience, joining Insud Pharma as shareholders.

2022-Present

mAbxience Biosimilar Development (With Subtitles)